2018 update to the HIV-TRePS system: The development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 8, 2018, Pages 2186-2196

  Revell, Andrew D ^a   Wang, Dechao ^a   Perez Elias, Maria Jesus ^b   Wood, Robin ^c   Cogill, Dolphina ^c   Tempelman, Hugo ^d   Hamers, Raph L ^e   Reiss, Peter ^e,f   Van Sighem, Ard I ^f   Rehm, Catherine A ^g   Pozniak, Anton ^h   Montaner, Julio S G ⁱ   Clifford Lane, H ^g   Larder, Brendan A ^a  

^a HIV Resistance Response Database Initiative (RDI)   (United Kingdom)

^b INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NDLOVU CARE GROUP   (South Africa)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f STICHTING HIV MONITORING   (Netherlands)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

ⁱ BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PROBABILITY; RANDOM FOREST; RECEIVER OPERATING CHARACTERISTIC; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; COMPUTER SIMULATION; DEVELOPING COUNTRY; DRUG SUBSTITUTION;

ADULT; ANTI-HIV AGENTS; COMPUTER SIMULATION; DEVELOPING COUNTRIES; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARAVIROC; PYRIDINES; PYRONES; QUINOLONES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85055130629     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky179     Document Type: Article

References (24)

1. WHO. HIV Drug Resistance Report 2017. www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/.
2. Montaner JS, Lima VD, Harrigan PR et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One 2014;9: e87872.
3. Nkambule R, Nuwagaba-Biribonwoha H, Mnisi Z et al. Substantial progress in confronting the HIV epidemic in Swaziland: first evidence of national impact. In: Abstracts of the Ninth IAS Conference on HIV Science, Paris, France, 2017. Abstract MOAX0204LB. International AIDS Society, Geneva, Switzerland.
4. Günthard HF, Aberg JA, Eron JJ et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312: 410-25.
5. Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2014;15 Suppl 1: 1-85.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
7. Degruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000;5: 41-8.
8. Conradie F, Wilson D, Basson A et al. The 2012 southern African ARV drug resistance testing guidelines. South Afr J HIV Med 2012;13: 162-7.
9. Gupta RK, Hill A, Sawyer AW et al. Virologicalmonitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9: 409-17.
10. Larder B, Wang D, Revell A et al. The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther 2007;12: 15-24.
11. Wang D, Larder B, Revell A et al. A comparison of three computational modellingmethods for the prediction of virological response to combination HIV therapy. Artif Intell Med 2009;47: 63-74.
12. Larder BA, Revell A, Mican JM et al. Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience. AIDS Patient Care STDS 2011;25: 29-36.
13. Revell AD, Wang D, Wood R et al. Computational models can predict response to HIV therapy without a genotype andmay reduce treatment failure in different resource-limited settings. J Antimicrob Chemother 2013;68: 1406-14.
14. Revell AD, Wang D, Wood R et al. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. J Antimicrob Chemother 2014;69: 1104-10.
15. Revell AD, Wang D, Wood R et al. An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. J Antimicrob Chemother 2016;71: 2928-37.
16. Revell AD, Wang D, Boyd MA et al. The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS 2011;25: 1855-63.
17. Wensing AM, Calvez V, Huldrych F et al. 2015 update of the drug resistance mutations in HIV-1. Top Antivir Med 2015;23: 132-41.
18. Revell AD, Wang D, Harrigan R et al. Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resourcelimited settings. J Antimicrob Chemother 2010;65: 605-7.
19. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach, Second Edition. Geneva, Switzerland: WHO, 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/.
20. Lecher S, Ellenberger D, Kim AA et al. Scale up of HIV viral load monitoring-seven sub-Saharan African countries. MMWR Morb Mortal Wkly Rep 2015;64: 1281-304.
21. Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis 2010;201 Suppl 1: S16-26.
22. Roberts T, Cohn J, Bonner K et al. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis 2016;62: 1043-8.
23. Hermans LE, Moorhouse M, Carmona S et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis 2018;18: 188-97.
24. Hassan AS, Nabwera HM, Mwaringa SM et al. HIV-1 virological failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther 2014;11: 9.